ENDRA Life Sciences Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated December 5, 2019, reports on a private placement offering closed by ENDRA Life Sciences Inc. on December 11, 2019. The Company, an emerging growth company incorporated in Delaware, entered into a Securities Purchase Agreement with accredited investors to raise capital.
Key Financial Metrics and Transaction Details
- Gross Proceeds: Approximately $7.9 million.
- Securities Issued: 6,338.490 shares of Series A Convertible Preferred Stock, 0.9 million shares of Common Stock, and Warrants exercisable for an aggregate of 8.2 million shares of Common Stock.
- Preferred Stock Terms: $1,000 issue price; 6.0% annual dividend rate (payable if declared); convertible at $0.87 per share.
- Warrant Terms: Exercise price of $0.87 per share; 5-year term from closing.
- Transaction Costs: 8.0% commission paid to placement agent; up to $35,000 expense reimbursement; issuance of a Placement Agent Warrant for 0.3 million shares.
- Use of Proceeds: Repayment of outstanding convertible notes due April 2020 and working capital/general corporate purposes.
Material Changes and Agreements
The filing details the entry into a Material Definitive Agreement (Item 1.01) and unregistered sales of equity securities (Item 3.02). The Company agreed to file a registration statement within 30 days of the closing to cover the resale of registrable securities. Failure to file by this deadline triggers a penalty of 1.0% of the aggregate amount invested per 30-day period.
Preferred Stock includes a forced conversion provision if the 10-day volume-weighted average price of Common Stock exceeds $1.74 and a registration statement is effective. Warrants may be forfeited if forced conversion conditions are met and notice is provided.
Outlook, Risks, and Contingencies
The primary contingency involves the timely filing of the registration statement to avoid penalty payments to investors. The Company has agreed to use commercially reasonable efforts to keep the registration statement effective until all registrable securities are sold or eligible for Rule 144 resale. The filing explicitly states it is not an offer to sell securities in the United States absent registration or an applicable exemption.
Key Facts for Investor Verification
- Verify the actual closing date and receipt of the $7.9 million gross proceeds.
- Confirm the filing of the Certificate of Designations for Series A Convertible Preferred Stock with the Delaware Secretary of State.
- Monitor the filing of the Registration Statement within 30 days of the closing to avoid 1.0% monthly penalty payments.
- Review the specific terms of the convertible notes due April 2020 to be repaid with these proceeds.
- Check the effective status of the registration statement for the resale of the 8.2 million warrant shares and converted preferred shares.